

Proposed Modifications to Existing Screening Programmes

Condition	Programme	Proposal	Year Submitted	Current Status
Bowel Cancer	BowelScreen Programme	To widen the age range eligibility of the BowelScreen programme to 50 to 74 years	2021	NSAC have asked HIQA to look at the evidence for this proposal. Proposals for cancer screening will be reviewed in context of the updated European Council Recommendation on cancer screening expected to be formally approved by the Council of the European Union in December 2022
Breast Cancer	BreastCheck Programme	To widen the age range eligibility of the BreastCheck programme to 45 to 74 years and to introduce a standardised Breast Density notification for all participants	2021	NSAC have asked HIQA to look at the evidence for this proposal. Proposals for cancer screening will be reviewed in context of the updated European Council Recommendation on cancer screening expected to be formally approved by the Council of the European Union in December 2022
Bowel Cancer	BowelScreen Programme	The adoption of a clinical guideline that will ensure BowelScreen is aligned with current clinical practice across the symptomatic service in the HSE	2021	Approved by Minister for Health in March 2022
Cervical Cancer	CervicalCheck Programme	The addition of a self-sampling HPV test to the CervicalCheck programme	2021	Ongoing consideration by NSAC and will be considered in context of the updated European Council Recommendation on cancer screening expected to be formally approved by the Council of the European Union in December 2022
Cervical Cancer	CervicalCheck Programme	To establish a dedicated catch up vaccination programme to work side by side with the cervical screening programme, specifically to offer HPV vaccination to those women in whom CIN2+ has been detected via CervicalCheck	2021	Outside of NSAC remit

Duchenne Muscular Dystrophy (DMD)	National Newborn Bloodspot Screening (NBS) Programme	The addition of Duchenne Muscular Dystrophy (DMD) to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme
Hunter Syndrome	National Newborn Bloodspot Screening (NBS) Programme	The addition of Hunter Syndrome to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme
Severe Combined Immunodeficiency (SCID)	National Newborn Bloodspot Screening (NBS) Programme	The addition of all forms of Severe Combined Immunodeficiency (SCID) to the NBS Programme	2021	Health Technology Assessment (HTA) underway, with final HTA report expected December 2022 for consideration by NSAC
Infantile Nephropathic Cystinosis	National Newborn Bloodspot Screening (NBS) Programme	The addition of Infantile Nephropathic Cystinosis (known as cystinosis) to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme
Metachromatic Leukodystrophy (MLD)	National Newborn Bloodspot Screening (NBS) Programme	The addition of Metachromatic Leukodystrophy (MLD) to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme
Sickle Cell Disease (SCD)	National Newborn Bloodspot Screening (NBS) Programme	The addition of Sickle Cell Disease to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme

Spinal Muscular Atrophy (SMA)	National Newborn Bloodspot Screening (NBS) Programme	The addition of Spinal Muscular Atrophy (SMA) to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme
22q11.2 Deletion Syndrome	National Newborn Bloodspot Screening (NBS) Programme	The addition of 22q11.2 Deletion Syndrome to the NBS Programme	2021	This condition is included in the preliminary review underway on expansion of the NBS programme
New Tech - (Newborn): Expanded use of Tandem Mass Spectrometry (TMS)	National Newborn Bloodspot Screening (NBS) Programme	The expanded use of Tandem Mass Spectrometry (TMS) in the NBS Programme to screen for multiple conditions in a single test	2021	This proposal will be considered as part of the current NSAC NBS expansion work programme
New Tech - (Adult Cancer): - kPlex consumable testing module	BowelScreen Programme, CervicalCheck Programme, BreastCheck Programme, Diabetic Retina Screen	The use of a point of care testing platform for cancer screening	2021	Further consideration deferred pending significant new evidence emerging
New Tech - (Newborn): Rapid Whole Genome Sequencing and Inborn Errors of Metabolism	National Newborn Bloodspot Screening (NBS) Programme	The use of Whole Genome Sequencing and Inborn Errors of Metabolism in the NBS Programme	2021	Further consideration deferred pending significant new evidence emerging